Arch Oncology Logo_RGB.jpg
Arch Oncology Secures $105 Million Series C Financing
April 27, 2021 07:00 ET | Arch Oncology
– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – – Series C co-led by new investors Eventide Asset...
Arch Oncology Logo_RGB.jpg
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 10, 2021 08:31 ET | Arch Oncology
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
Arch Oncology Logo_RGB.jpg
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
April 07, 2021 08:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
Arch Oncology Logo_RGB.jpg
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021
March 10, 2021 17:09 ET | Arch Oncology
-- Two presentations to highlight AO-176’s potential in lymphoma and T-ALL -- BRISBANE, Calif. and ST. LOUIS, March 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage...
Arch Oncology Logo_RGB.jpg
Arch Oncology to Participate in Upcoming Conferences
February 16, 2021 09:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
Arch Oncology Logo_RGB.jpg
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
February 09, 2021 09:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
Arch Oncology Logo_RGB.jpg
Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 09:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
Arch Oncology Logo_RGB.jpg
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma
December 07, 2020 09:00 ET | Arch Oncology
-- First Dedicated Clinical Trial of an Anti-CD47 Antibody in Multiple Myeloma ---- At ASH 2020, New Preclinical Data Presented on AO-176 in Multiple Myeloma -- BRISBANE, Calif. and ST. LOUIS, Dec. ...
Arch Oncology Logo_RGB.jpg
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
December 06, 2020 10:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
Arch Oncology Logo_RGB.jpg
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer
November 16, 2020 09:00 ET | Arch Oncology
BRISBANE, Calif. and ST. LOUIS, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...